BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sakai H, Zhou Y, Miyauchi Y, Suzuki Y, Ikeno Y, Kon R, Ikarashi N, Chiba Y, Hosoe T, Kamei J. Increased 20S Proteasome Expression and the Effect of Bortezomib during Cisplatin-Induced Muscle Atrophy. Biol Pharm Bull 2022;45:910-8. [PMID: 35786599 DOI: 10.1248/bpb.b22-00177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Klassen P, Schiessel DL, Baracos VE. Adverse effects of systemic cancer therapy on skeletal muscle: myotoxicity comes out of the closet. Curr Opin Clin Nutr Metab Care 2023. [PMID: 36942895 DOI: 10.1097/MCO.0000000000000922] [Reference Citation Analysis]
2 Yalçın T, Kaya S. Thymoquinone may alleviate cisplatin-induced muscle atrophy in rats by regulating mitofusin 2 and meteorin-like levels. Comp Clin Pathol 2023. [DOI: 10.1007/s00580-023-03442-9] [Reference Citation Analysis]
3 Hain BA, Waning DL. Bone-Muscle Crosstalk: Musculoskeletal Complications of Chemotherapy. Curr Osteoporos Rep 2022;20:433-41. [PMID: 36087213 DOI: 10.1007/s11914-022-00749-4] [Reference Citation Analysis]
4 Sakai H, Suzuki Y, Miyauchi Y, Sato F, Ando Y, Kon R, Ikarashi N, Chiba Y, Kamei J, Hosoe T. Downregulation of Sparc-like protein 1 during cisplatin-induced inhibition of myogenic differentiation of C2C12 myoblasts. Biochem Pharmacol 2022;:115234. [PMID: 36041542 DOI: 10.1016/j.bcp.2022.115234] [Reference Citation Analysis]
5 Canfora I, Tarantino N, Pierno S. Metabolic Pathways and Ion Channels Involved in Skeletal Muscle Atrophy: A Starting Point for Potential Therapeutic Strategies. Cells 2022;11:2566. [DOI: 10.3390/cells11162566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]